Imatinib Mesylate, Active Pharmaceutical Ingredients, product, supplier, suppliers, vendor, vendors, price, prices

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Imatinib-Mesylate Taj API

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Imatinib Mesylate Manufacturers in India Suppliers Imatinib Mesylate Exporters Distributors Imatinib Mesylate api active pharmaceuticals ingredients Imatinib Mesylate manufacturers Side Effects bulk drugs raw material Imatinib Mesylate companies Side Effects Importers Imatinib Mesylate Imatinib Mesylate Exporters Imatinib Mesylate exporters FDA Imatinib Mesylate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Imatinib Mesylate manufacturing pharmaceutical drugs pharmaceutical intermediates Imatinib Mesylate pharmaceutical chemicals pharmaceutical raw materials Imatinib Mesylate active pharmaceutical ingredients Imatinib Mesylate committee active pharmaceutical ingredients manufacturer Imatinib Mesylate Active Pharmaceutical Ingredients manufacturer Imatinib Mesylate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Imatinib Mesylate, Imatinib Mesylate manufacturer India, Imatinib Mesylate product, Imatinib Mesylate products, Api preparation, Certificate of Analysis API manufacturer product, Imatinib Mesylate anti ulcer product, Certificate of Origin COA Imatinib Mesylate COS Imatinib Mesylate, pharmaceutical generic, pharmaceutical drug, medical, Imatinib Mesylate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Imatinib Mesylate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Imatinib Mesylate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Imatinib Mesylate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Imatinib Mesylate ingredients, api, HIV Imatinib Mesylate, tablets, capsules, syrup & protein Imatinib Mesylate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Imatinib Mesylate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Imatinib Mesylate WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

pharma Imatinib Mesylate

HOME >> API >> API List 2 >> Imatinib Mesylate >> Interaction

INTERACTION
Imatinib Mesylate

Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of , increased oral-dose clearance by 3.8-fold, which significantly (p < 0.05) decreased mean Cmax and AUC. If alternative treatment cannot be administered
Agents Inhibiting CYP3A Metabolism

There was a significant increase in exposure to imatinib (mean Cmax and AUC increased by 26% and 40%, respectively) in healthy subjects when was co-administered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution is recommended when administering with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Grapefruit juice may also increase plasma concentrations of imatinib and should be avoided. Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations.
Interactions with Drugs Metabolized by CYP3A4.

increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by . Particular caution is recommended when administering

with CYP3A4 substrates that have a narrow therapeutic window (e.g., alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus or tacrolimus).
Interactions with Drugs Metabolized by CYP2D6

In vitro, inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity. Systemic exposure to substrates of CYP2D6 is expected to be increased when coadministered with . No specific studies have been performed and caution is recommended.
Interaction with Acetaminophen

In vitro, inhibits acetaminophen O-glucuronidation (Ki value of 58.5 µM) at therapeutic levels.

Systemic exposure to acetaminophen is expected to be increased when co-administered with . No specific studies in humans have been performed and caution is recommended.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE

SIDE EFFECTS

PRECAUTIONS

INTERACTION >>

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Api Manufacturer,Export,Supplies,Manufacturing

Gabapentin	Gemcitabine Hcl	Glimepiride	Granisetron Hcl	Ibandronate Sodium	Imatinib Mesylate	Irbesartan	Irinotecan Hcl	Isradipine	Lamotrigine
Lercanidipine	Letrozole	Losartan Potassium	Loteprednol Etabonate	Magnesium Valproate	Meloxicam	Memantine Hcl	Mesalazine	Metamizol Magnesium	Metaxalone
Metformin Hcl	Metoprolol Tartrate	Mifepristone	Mirtazapine	Modafinil	Mometasone Furoate	Naltrexone Hcl	Netaglinide

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.